Wednesday - April 15, 2026

Polycythemia Vera Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharma, Perseus Proteomics

The Key Polycythemia Vera Companies:in the market include – Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Protagonist Therapeutics, Inc., Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.   DelveInsight’s report, “Polycythemia Vera Market Insights, … Continue reading

Becker Muscular Dystrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Epirium Bio, Immuno Forge, Italfarmaco, Santhera Pharmaceuticals

Becker Muscular Dystrophy pipeline constitutes 8+ key companies continuously working towards developing 8+ Becker Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   “Becker Muscular Dystrophy Pipeline Insight, 2026“ … Continue reading

NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan

The Key Non-Small Cell Lung Cancer Companies in the market include 0- AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan Oncology/ Taiho Pharma, Genentech/Roche, Betta Pharma/ Xcovery, Pfizer, Takeda Pharmaceuticals, AstraZeneca, Janssen, Boehringer Ingelheim, Pfizer, … Continue reading

Peripheral Artery Disease Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Ixaka Ltd, Hemostemix Inc., Caladrius Biosciences, Humacyte

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Peripheral Artery Disease pipeline constitutes 20+ key companies continuously working towards developing 22+ Peripheral Artery Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading

Pulmonary Fibrosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeut

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pulmonary Fibrosis pipeline constitutes 110+ key companies continuously working towards developing 140+ Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading

Degenerative Disc Disease Clinical Trial Analysis 2026: Recent FDA Clearances, Ongoing Clinical Studies, and Emerging Treatment Landscape by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutic

Degenerative Disc Disease Pipeline According to DelveInsight’s evaluation, the global Degenerative Disc Disease (DDD) pipeline comprises more than 15 prominent companies actively advancing over 15 therapeutic candidates. The analysis encompasses clinical trials, therapeutic approaches, mechanisms of action, routes of administration, … Continue reading